Published: 2/3/2026 6:12:51 AM

This is a news from the Finwire news agency Disclaimer


Finwire about PharmaLundensis AB: Pharmalundensis is traded today on Spotlight ex-rights in the rights issue

The research company Pharmalundensis is traded today, February 3, on Spotlight Stock Market ex-rights in the rights issue. The terms are 2:3, meaning that three existing shares entitle the holder to subscribe for two new shares at the subscription price of SEK 0.50 per share. The subscription period runs from February 6 to 20, and trading in subscription rights takes place February 6 to 17.

Read more about PharmaLundensis AB